#MAP2026: Latest #ClinicalResearch in #TNBC identifies potential novel drivers of chromosome instability linked to immune evasion and #biomarkers of early recurrence post #chemotherapy, expanding knowledge of this aggressive cancer. #ESMODailyReporter:https://ow.ly/lCm550ZMxtZ

AR-positive #TNBC offers a vital target, but single-agent anti-AR therapies hit steep clinical hurdles. This review outlines how combining AR antagonists with other therapeutic strategies overcomes resistance. #medsky

To read: doi.org/10.1007/s115...

#currentmedicalscience #Oncology

⚠️Cancer update: the hardest.
Liver lesion has spread (stage IV) - spine, pelvis, legs & spleen. I've started radiotherapy, chemo and immuno but sadly it's not curable. I will fight so hard for as long as I can. Thank you so much for the strength you've always given to me.🤍🎗️
#breastcancer #tnbc

Do you have metastatic triple negative breast cancer #TNBC that has grown or spread after treatment? You may be eligible for the #YUANTNBC clinical trial. Follow the link below or call (414)-314-0471 to learn more.

clinicaltrials.cedars-sinai.edu/view/IIT2022...

Groundbreaking Approval for Lifesaving Treatment in Europe for TNBC Patients #None #Sacituzumab #TNBC #Pembrolizumab

Detección de DNA tumoral circulante libre de tejido pronostica recurrencia en pac c/CA mama triple negativo c/tiempos comparables c/pruebas multivariantes, apoya detección de enfermedad residual libre de tejido cuando no se dispone de tejido #ctDNA #TNBC jamanetwork.com/journals/jam...